Efavirenz and CYP2B6 polymorphism:: Implications for drug toxicity and resistance

被引：38
|
作者：
Nolan, D
Phillips, E
Mallal, S
机构：
[1] Murdoch Univ, Ctr Clin Immunol & Biomed Stat, Royal Perth Hosp, Perth, WA 6000, Australia
[2] Univ British Columbia, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V5Z 1M9, Canada
来源：
CLINICAL INFECTIOUS DISEASES | 2006年 / 42卷 / 03期
关键词：
D O I：
10.1086/499369
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：408 / 410
页数：3
相关论文
共 50 条
  • [31] The clinical spectrum and G516T CYP2B6 single-nucleotide polymorphism in efavirenz drug-induced liver injury
    Sonderup, Mark
    Abdullah, Gadija
    Gogela, Neliswa
    Spearman, C. Wendy
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2018, 108 (08): : 692 - 692
  • [32] Single Heteroatom Substitutions in the Efavirenz Oxazinone Ring Impact Metabolism by CYP2B6
    Cox, Philip M.
    Bumpus, Namandj N.
    CHEMMEDCHEM, 2016, 11 (23) : 2630 - 2637
  • [33] CYP2B6*6 or Not CYP2B6*6-That Remains a Question for Precision Medicine and Ketamine!
    Cook-Sather, Scott D.
    Adamson, Peter C.
    Li, Jin
    Hakonarson, Hakon
    ANESTHESIOLOGY, 2016, 125 (06) : 1085 - 1087
  • [34] Prenatal efavirenz exposure is independently associated with maternal, but not fetal CYP2B6 genotype
    Eniayewu, Oluwasegun
    Akinloye, Abdulafeez
    Shenkoya, Babajide
    Azuka, Uche
    Bolaji, Oluseye
    Adejuyigbe, Ebunoluwa
    Owen, Andrew
    Olagunju, Adeniyi
    PHARMACOGENETICS AND GENOMICS, 2024, 34 (08): : 253 - 260
  • [35] Effect of CYP2B6 genotype on the plasma efavirenz exposure in an African HIV woman
    Le Dauphin, Emmanuelle
    Barrail-Tran, Aurelie
    Brunet, Anne
    Bouligand, Jerome
    Goujard, Cecile
    Taburet, Anne-Marie
    PHARMACY WORLD & SCIENCE, 2009, 31 (02): : 331 - 332
  • [36] Would a CYP2B6 test help HIV patients being treated with efavirenz?
    Sukasem, Chonlaphat
    Sungkanuparph, Somnuek
    PHARMACOGENOMICS, 2013, 14 (09) : 999 - 1001
  • [37] Potent inhibition of efavirenz secondary metabolism by CYP2B6 inhibitors in vitro.
    Huh, W.
    Jones, D. R.
    Jeong, S.
    Flockhart, D. A.
    Desta, Z.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S43 - S44
  • [38] Genetic variants of CYP2B6 decrease rate of efavirenz metabolism in vitro.
    Desta, Z
    Ward, BA
    Flockhart, DA
    Richter, T
    Klein, K
    Zanger, UM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P24 - P24
  • [39] Frequency of CYP2B6 Alleles in Major Iranian Ethnicities, Affecting Response to Efavirenz
    Mardi, Parham
    Tavakoli-Far, Bahareh
    Nia, Samira Sheibani
    Jazayeri, Roshanak
    Houshmand, Massoud
    GENETICS RESEARCH, 2022, 2022
  • [40] Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection
    Jamshidi, Y.
    Moreton, M.
    McKeown, D. A.
    Andrews, S.
    Nithiyananthan, T.
    Tinworth, L.
    Holt, D. W.
    Sadiq, S. T.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (12) : 2614 - 2619
12345